119
Participants
Start Date
May 31, 2014
Primary Completion Date
May 6, 2019
Study Completion Date
May 6, 2019
NC-6004
NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
Gemcitabine
Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
Multiprofile Hospital for Active Treatment Serdika EOOD, Sofia
Complex Oncology Center - Shumen EOOD, Shumen
ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda, Milan
Fundeni Clinical Institute, Bucharest
University of North Carolina at Chapel Hill, Chapel Hill
Coltea Clinical Hospital, Bucharest
Wojewodzki Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, Krakow
University Hospitals Case Medical Center, Cleveland
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST, Meldola
Northwestern University Feinberg School of Medicine, Chicago
Med-Polonia Sp. z o.o., Poznan
University of Oklahoma Health Sciences Center, Oklahoma City
University of Texas Southwestern Medical Center, Dallas
MD Anderson Cancer Center, Houston
California Cancer Associates for Research and Excellence, Encinitas
UC San Diego Moores Cancer Center, La Jolla
Pacific Hematology Oncology Associates, San Francisco
Oncology Center Sfantul Nectarie, Craiova
Prof Dr I Chiricuta Institute of Oncology, Cluj-Napoca
Euroclinic Oncology Center SRL, Iași
Institutul Regional de Oncologie Iasi, Iași
Tufts Medical Center, Boston
NanoCarrier Co., Ltd.
INDUSTRY